Nuwellis, Inc. (NUWE)
| Market Cap | 2.63M -17.6% |
| Revenue (ttm) | 9.01M +8.4% |
| Net Income | -11.32M |
| EPS | -145.78 |
| Shares Out | 3.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 126,708 |
| Open | 0.7518 |
| Previous Close | 0.7459 |
| Day's Range | 0.7200 - 0.7650 |
| 52-Week Range | 0.7112 - 172.8970 |
| Beta | 0.23 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 11, 2026 |
About NUWE
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Pra... [Read more]
Financial Performance
In 2025, Nuwellis's revenue was $8.27 million, a decrease of -5.38% compared to the previous year's $8.74 million. Losses were -$17.52 million, 64.9% more than in 2024.
Financial StatementsNews
Nuwellis announces commercial momentum for Aquadex SmartFlow system
Nuwellis (NUWE) announced continued commercial momentum for its Aquadex SmartFlow system, with 31 consoles sold year-to-date in 2026. The company’s year-to-date console performance already exceeds ful...
Nuwellis Reports Strong Aquadex Console Adoption, with 31 Aquadex SmartFlow Consoles Sold Year-to-Date, Meaningfully Expanding Recurring Revenue Opportunity
Year-to-date console sales exceed full-year console sales in seven of the past 10 years, putting Nuwellis on pace for one of its strongest years in console placements Year-to-date console sales exceed...
Nuwellis Strengthens Organization with Appointment of Brian Johnson as Director of Quality and Regulatory Affairs
Experienced medical device quality and regulatory leader brings 13 years of experience supporting quality systems, regulatory compliance, audits and product development Experienced medical device qual...
Nuwellis Advances Financial Efficiency Strategy with Improved Gross Margins
MINNEAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, highlights conti...
Nuwellis, Atrility Medical announce AtriAmp co-promotion and distribution pact
Nuwellis (NUWE) and Atrility Medical announced that they have entered into a co-promotion and distribution agreement for Atrility’s AtriAmp device. Under the agreement, the companies will begin an ini...
Nuwellis Expands Critical Care Portfolio Through Strategic Commercial Agreement with Atrility Medical
Agreement expands Nuwellis' pediatric and critical care portfolio and provides a milestone-based pathway to U.S. distribution Agreement expands Nuwellis' pediatric and critical care portfolio and prov...
Nuwellis Slides: Investor presentation
Nuwellis has posted slides in relation to its latest quarterly earnings report, which was published on August 25, 2026.
Nuwellis files to sell 1.35M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.35M shares of common stock. The company is not selling any…
Nuwellis Registration statement: Registration filing
Nuwellis filed a registration statement on August 18, 2026, providing details about a securities offering with the SEC.
Nuwellis Earnings Call Transcript: Q2 2026
Revenue grew 14% year-over-year in Q2 2026, with gross margin rising to 76% and net loss narrowing to $4.8 million. Strategic focus remains on expanding Aquadex utilization, pediatric and critical care growth, and disciplined capital allocation.
Nuwellis Earnings release: Q2 2026
Nuwellis released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Nuwellis Quarterly report: Q2 2026
Nuwellis has published its Q2 2026 quarterly earnings report on August 13, 2026.
Nuwellis Reports Second Quarter 2026 Financial Results and Business Highlights Focused on Double Digit Revenue Growth and Expanded Gross Margin
Recent capital raise and warrant exercises extend cash runway through second quarter of 2027 Conference call begins at 9:00 a.m. Eastern time today MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nuwel...
Nuwellis Strengthens Product Development Organization with Appointment of Dale Brady as Principal R&D Engineer
MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced t...
Nuwellis Announces Next-Generation Aquadex Platform Strategy to Expand Future Critical Care Applications
Development initiatives to strategically extend Aquadex® platform capabilities for future immunomodulation, extracorporeal blood purification, and advanced critical care therapies Development initiati...
Nuwellis prices $3.4M at-the-market offering at $2.59 per share
Nuwellis (NUWE) announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 1,310,890 shares of the Company’s common...
Nuwellis Announces Pricing of $3.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Nuwellis also received $3.1 Million from the Exercise of Previously Issued Warrants from the June 2026 Public Offering Nuwellis also received $3.1 Million from the Exercise of Previously Issued Warran...
Why Is Penny Stock Nuwellis (NUWE) Up Today?
Nuwellis stock was on the rise after the company announced a study that was published in a peer-reviewed journal.
Nuwellis Announces Acceptance by Frontiers in Pediatrics of New Single-Center Retrospective Study Supporting Alternative Anticoagulation Strategy for Aquadex Ultrafiltration Therapy
Peer-reviewed research demonstrates epoprostenol maintained circuit performance without observed bleeding events or increased vasoactive support in critically ill pediatric patients Peer-reviewed rese...
Nuwellis Expands Pediatric Footprint with First Aquadex SmartFlow® Installations in Wisconsin
MINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces its exp...
Nuwellis Announces Preliminary Revenue Results for the Second Quarter 2026 Showing Double Digit Growth
Company expects preliminary revenue year-over-year growth of 14% for second quarter 2026 and 20% for the first half of 2026 as Aquadex Ultrafiltration platform drives continued commercial momentum Nuw...
Nuwellis awarded U.S. patent for Dual Lumen Catheter
Nuwellis (NUWE) announced that the U.S. Patent and Trademark Office , or USPTO, has issued U.S. Patent No. 12,678,592, covering the company’s Dual Lumen Catheter, a peripheral dual-lumen catheter desi...
Nuwellis Awarded U.S. Patent for Novel Catheter Technology Designed to Enhance Extracorporeal Therapies
Innovation enables customizable catheter length while maintaining structural integrity during ultrafiltration, dialysis, and continuous renal replacement therapy modalities Innovation enables customiz...
Nuwellis to Showcase Aquadex Therapy at KidneyBee Summit 2026
MINNEAPOLIS, July 07, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, announces its par...
Nuwellis Proxy statement: Proxy filing
Nuwellis filed a proxy statement on July 7, 2026, providing details for shareholder voting and corporate governance matters.